Company Filing History:
Years Active: 2018-2023
Title: Jason Erskine: Innovator in Canine Cancer Treatment
Introduction
Jason Erskine is a prominent inventor based in Omaha, NE (US), known for his significant contributions to veterinary medicine. He holds a total of seven patents, focusing primarily on innovative treatments for cancer in dogs. His work has the potential to improve the quality of life for countless pets suffering from this disease.
Latest Patents
Among his latest patents, Jason has developed antibodies against canine PD-1. This invention discloses antibodies that possess specific sequences and a high binding affinity for canine PD-1. The application of these antibodies is aimed at treating cancer in dogs, showcasing a significant advancement in veterinary oncology. Another notable patent involves PD-L1 antibodies that bind to canine PD-L1. This disclosure describes caninized antibodies with specific properties, detailing the epitopes of canine PD-L that interact with these antibodies. The use of these caninized anti-canine PD-L1 antibodies also targets cancer treatment in dogs, further emphasizing Jason's commitment to improving animal health.
Career Highlights
Jason Erskine is currently employed at Intervet Inc., a company dedicated to advancing veterinary medicine. His innovative work has positioned him as a key figure in the field, contributing to the development of effective cancer treatments for dogs.
Collaborations
Jason collaborates with notable colleagues, including Mohamad A Morsey and Yuanzheng Zhang. Their combined expertise enhances the research and development of groundbreaking veterinary therapies.
Conclusion
In summary, Jason Erskine is a dedicated inventor whose work in canine cancer treatment is making a significant impact in veterinary medicine. His innovative patents and collaborations reflect his commitment to improving the health and well-being of dogs.